Collegium Pharmaceutical Inc [NASDAQ: COLL] stock went on a downward path that fall over -0.33% on Friday, amounting to a one-week price increase of more than 1.34%.
Over the last 12 months, COLL stock rose by 1.86%. The one-year Collegium Pharmaceutical Inc stock forecast points to a potential upside of 22.44. The average equity rating for COLL stock is currently 1.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.08 billion, with 32.23 million shares outstanding and 31.12 million shares in the current float. Compared to the average trading volume of 459.42K shares, COLL stock reached a trading volume of 264277 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Collegium Pharmaceutical Inc [COLL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for COLL shares is $43.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on COLL stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for Collegium Pharmaceutical Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 10, 2025. The new note on the price target was released on July 30, 2024, representing the official price target for Collegium Pharmaceutical Inc stock. Previously, the target price had yet another raise from $41 to $44, while Jefferies kept a Buy rating on COLL stock.
The Average True Range (ATR) for Collegium Pharmaceutical Inc is set at 1.24, with the Price to Sales ratio for COLL stock in the period of the last 12 months amounting to 1.79. The Price to Book ratio for the last quarter was 4.59, with the Price to Cash per share for the same quarter was set at 4.49. Price to Free Cash Flow for COLL in the course of the last twelve months was 5.59 with Quick ratio for the last quarter at 0.88.
COLL Stock Performance Analysis:
Collegium Pharmaceutical Inc [COLL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.34. With this latest performance, COLL shares gained by 8.56% in over the last four-week period, additionally plugging by 3.93% over the last 6 months – not to mention a rise of 1.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for COLL stock in for the last two-week period is set at 62.31, with the RSI for the last a single of trading hit 66.60, and the three-weeks RSI is set at 58.11 for Collegium Pharmaceutical Inc [COLL]. The present Moving Average for the last 50 days of trading for this stock 30.80, while it was recorded at 33.35 for the last single week of trading, and 34.28 for the last 200 days.
Insight into Collegium Pharmaceutical Inc Fundamentals:
Collegium Pharmaceutical Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.88 and a Current Ratio set at 0.97.
Collegium Pharmaceutical Inc [COLL] Institutonal Ownership Details
There are presently around $121.64%, or 123.67%% of COLL stock, in the hands of institutional investors. The top three institutional holders of COLL stocks are: BLACKROCK INC. with ownership of 5.79 million shares, which is approximately 17.9214%. PACER ADVISORS, INC., holding 3.41 million shares of the stock with an approximate value of $$109.75 million in COLL stocks shares; and PACER ADVISORS, INC., currently with $$84.84 million in COLL stock with ownership which is approximately 8.1501%.
